Eisai Grants Core Biomedicine Global License to Oncology Pipeline
Japanese pharmaceutical company Eisai has entered into an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programs. The deal allows CORE Biomedicine the rights to develop and commercialize a portfolio of cancer therapies originally discovered by Eisai, focusing on key molecular drivers in various cancers. CORE plans to integrate these assets into its precision medicine strategy using a lineage-based approach that aims to identify broader patient populations beyond traditional genomic markers. This licensing agreement is part of CORE's efforts to expand its therapeutic offerings and address significant unmet medical needs across multiple cancer types.
Topics: Biotech Licensing Oncology Pharmaceuticals